60 Degrees PharmaceuticalsSXTP
SXTP
About: 60 Degrees Pharmaceuticals Inc operates as a specialty pharmaceutical company with the goal of using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The firm's pipeline products under development cover development programs for COVID-19, fungal, tick-borne, and other viral diseases.
Employees: 3
0
Funds holding %
of 7,425 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
376% more capital invested
Capital invested by funds: $41.4K [Q3] → $197K (+$156K) [Q4]
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
14% more funds holding
Funds holding: 7 [Q3] → 8 (+1) [Q4]
4.89% more ownership
Funds ownership: 1.77% [Q3] → 6.66% (+4.89%) [Q4]
Research analyst outlook
We haven’t received any recent analyst ratings for SXTP.
Financial journalist opinion
Based on 3 articles about SXTP published over the past 30 days
Neutral
GlobeNewsWire
1 week ago
Babesiosis Disease Burden in United States is Substantially Higher Than Official Estimates, According to Preliminary Results of 60 Degrees Pharma Survey
60 Degrees Pharma survey suggests babesiosis affects up to 3M Americans—vastly more than CDC data—and may underlie millions of chronic fatigue cases.
Neutral
GlobeNewsWire
2 weeks ago
Geoff Dow, PhD, Infectious Disease Product Development Expert, to Discuss Babesiosis at Healing Lyme Summit, April 15-21
WASHINGTON, April 10, 2025 (GLOBE NEWSWIRE) -- Geoff Dow, infectious disease product development expert and chief executive officer of 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60 Degrees” or the “Company”), will participate in a scientific discussion on the management and treatment of babesiosis during the April 15–21 Healing Lyme Summit. Babesiosis is a rapidly emerging tick-borne disease often found as a coinfection with Lyme disease.
Neutral
GlobeNewsWire
3 weeks ago
Sixty Degrees Pharmaceuticals Announces Patent License Agreement to Advance Development of Tafenoquine for Babesiosis Treatment and Prevention with Yale School of Medicine and Yale School of Public Health
60 Degrees Pharma partners with Yale to develop tafenoquine for treating and preventing babesiosis, a severe tick-borne disease with limited treatments.
Neutral
Accesswire
2 months ago
60 Degrees Pharmaceuticals and Fathom Holdings Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
ORLANDO, FL / ACCESS Newswire / February 21, 2025 / RedChip Companies will air interviews with 60 Degrees Pharmaceuticals, Inc. (Nasdaq:SXTP) and Fathom Holdings Inc. (Nasdaq:FTHM) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV this Saturday, February 22, at 7 p.m. Eastern Time (ET).
Neutral
GlobeNewsWire
2 months ago
60 Degrees Pharmaceuticals, Inc. Announces 1:5 Reverse Stock Split
WASHINGTON, Feb. 20, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, announced today that it will effect a 1-for-5 reverse stock split (“Reverse Stock Split”) of its common stock, par value $0.0001 per share (“Common Stock”). The Common Stock will continue to trade on The Nasdaq Capital Market under the existing symbol “SXTP” and will begin trading on a split-adjusted basis when the market opens on February 24, 2025.
Neutral
GlobeNewsWire
2 months ago
Sixty Degrees Pharmaceuticals to Ensure Continuity of Tafenoquine Supply in U.S. by Importing Limited Quantity of KODATEF®
WASHINGTON, Feb. 11, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60 Degrees” or the “Company”), pharmaceutical company today announced that the United States Food and Drug Administration (FDA) does not object to the Company's plan to import KODATEF® (tafenoquine) from Australia as a one-time, preemptive measure against any near-term disruption in the U.S. supply of ARAKODA® (tafenoquine). ARAKODA is an antimalarial indicated for the prophylaxis of malaria in patients aged 18 years and older in the United States (U.S.) It is sold under the brand name KODATEF in Australia, where it is indicated for the prevention of malaria in adults 18 years of age and above.
Neutral
GlobeNewsWire
2 months ago
60 Degrees Pharma Announces Closing of $1.075 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
60 Degrees Pharma closed a $1.075M registered direct offering, raising $2.118M YTD to fund operations. H.C. Wainwright & Co. acted as placement agent.
Neutral
GlobeNewsWire
2 months ago
60 Degrees Pharma Announces $1.075 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
60 Degrees Pharma (SXTP) announces a $1.075M registered direct offering, issuing stock and warrants to fund working capital and corporate initiatives.
Neutral
GlobeNewsWire
2 months ago
60 Degrees Pharma Announces Closing of $1.043 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
WASHINGTON, Jan. 30, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase and sale of an aggregate of 1,021,549 shares of its common stock at a purchase price of $1.021 per share. In addition, in a concurrent private placement, the Company issued unregistered short-term warrants to purchase up to an aggregate of 2,043,098 shares of common stock.
Neutral
GlobeNewsWire
3 months ago
60 Degrees Pharma Announces IRB Approval of Phase II Study to Evaluate Tafenoquine for Chronic Babesiosis
Investigational Review Board (IRB) approval has been granted for the open-label study to evaluate tafenoquine for treatment of patients with a presumptive diagnosis of chronic babesiosis in outpatient settings. Enrollment expected to commence Q3 2025.
Charts implemented using Lightweight Charts™